Arkolith/Insider Trading/GYRE/Form 4

Ye Weiguo

Chief Operating OfficerGYRE THERAPEUTICS, INC. (GYRE) · full profile →Form 4 · filed May 18, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$195K
Net Open-Market Flow
-$195K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 15, 2026Option exercise(M)13K$0.75$10K713K
May 15, 2026Sell(S)13K$6.65$87K700K
May 14, 2026Option exercise(M)16K$0.75$12K716K
May 14, 2026Sell(S)16K$6.91$108K700K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 15, 2026Option exercise(M)13K—$0936K
May 14, 2026Option exercise(M)16K—$0950K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001140361-26-021889) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for GYRE THERAPEUTICS, INC.

Build

Ask your agent about GYRE insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001140361-26-021889"
Ask your agent
Use Arkolith to summarize insider buying and selling at GYRE THERAPEUTICS, INC.
over the last 90 days and cite the filings.